A Therapeutic Patent Overview of MDM2/X-targeted Therapies (2014–2018)

Expert Opinion on Therapeutic Patents - United Kingdom
doi 10.1080/13543776.2019.1582645
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Targeted Therapies for Alzheimer's Disease: An Overview

2017English

P53-Mdm2 Pathway: Evidences for a New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia

Frontiers in Pharmacology
Pharmacology
2016English

Targeted Cancer Therapies

Chinese Journal of Cancer
2011English

Enhancing the Therapeutic Effects of in Vitro Targeted Radionuclide Therapy of 3D Multicellular Tumor Spheroids Using the Novel Stapled MDM2/X-p53 Antagonist PM2

EJNMMI Research
Nuclear MedicineRadiologyImaging
2020English

Dermatomyositis: A Slow Path Towards Targeted Therapies or Will Conventional Therapies Prevail?

British Journal of Dermatology
DermatologyMedicine
2018English

Targeted Therapies for Pancreatic Cancer

Cancers
Cancer ResearchOncology
2018English

Expanding Targeted Therapies for NSCLC

Cancer Discovery
Oncology
2014English

MS28.04 Combination With Targeted Therapies

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Paradox of B Cell–targeted Therapies

Journal of Clinical Investigation
Medicine
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy